Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,547 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05765500 | RecoverPC: Relugolix vs GnRH Agonist in Quality of Life | recruiting | Phase 2 | 110 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06325046 | Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer | recruiting | N/A | 164 | Mayo ClinicOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06604130 |
| Plasma Exosome RNA to Diagnose Prostate Cancer(exo-PRECISE) |
| enrolling by invitation |
| N/A |
| 1,600 |
| Xijing HospitalOTHER |
| 1 |
| Jul 30, 2026 |
| clinicaltrials |
| NCT07203482 | Clinical Outcomes in Prostate Cancer Patients Undergoing HIFU Ablation | recruiting | — | 300 | NYU Langone HealthOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07288359 | Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 205 | Novartis PharmaceuticalsINDUSTRY | 10 | Jul 30, 2026 | clinicaltrials |
| NCT07737457 | MICRO-ultrasound Guided Prostate SBRT(MICRO-S) | not yet recruiting | N/A | 112 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT01542021 | Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer | completed | N/A | 41 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT03031821 | Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome(PRIME) | terminated | Phase 3 | 166 | Canadian Urologic Oncology GroupOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT03246347 | A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer | active not recruiting | Phase 2 | 40 | Wake Forest University Health SciencesOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05327465 | Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy | recruiting | N/A | 62 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05345444 | Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE)(RTIRE) | active not recruiting | N/A | 48 | Weill Medical College of Cornell UniversityOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07733440 | PROstate Cancer Risk Calculator for ACTionable Clinical Decision-making in Nigeria(PROACT) | not yet recruiting | N/A | 89 | Ahmadu Bello UniversityOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07735273 | eMindExCare for Prostate Cancer Patients Undergoing Active Treatment(eMindExCare) | not yet recruiting | N/A | 60 | The University of Hong KongOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT04484818 | Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study | active not recruiting | Phase 3 | 27 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jul 28, 2026 | clinicaltrials |
| NCT05844761 | Real-time Motion Management During Prostate and Lung Radiotherapy(REMIND) | active not recruiting | N/A | 132 | Region SkaneOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT06441994 | Clinical Trial of Targeted Alpha Therapy Using [At-211]PSMA-5 for Prostate Cancer(Alpha-PS1) | active not recruiting | Phase 1 | 15 | Osaka UniversityOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07730151 | Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer. | not yet recruiting | Phase 2 | 200 | RenJi HospitalOTHER | 0 | Jul 28, 2026 | clinicaltrials |
| NCT07730203 | Photon-Counting Computed Tomography-Based Urethral Visualization Without Catheterization for Radiotherapy Planning: A Prospective Pilot Study Under ANTHEM(PURE-CT/ANTHEM) | recruiting | — | 20 | Istituto Clinico HumanitasOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07730580 | Study of XNW5004 Tablets in Advanced Prostate Cancer(XNW5004 Tablet) | not yet recruiting | Phase 2 | 242 | Evopoint Biosciences Inc.INDUSTRY | 0 | Jul 28, 2026 | clinicaltrials |
| NCT05404139 | Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)(DIRECT) | recruiting | Phase 2 | 352 | University Health Network, TorontoOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07096999 | SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy | recruiting | — | 60 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07727473 | Preoperative Semaglutide Prior to Radical Prostatectomy | not yet recruiting | Early Phase 1 | 20 | Banner HealthOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT00002540 | Screening for Prostate Cancer in Older Patients (PLCO Screening Trial) | active not recruiting | N/A | 76,685 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2026 | clinicaltrials |
| NCT00102544 | Use of Tracking Devices to Locate Abnormalities During Invasive Procedures | enrolling by invitation | N/A | 3,894 | National Institutes of Health Clinical Center (CC)NIH | 1 | Jul 24, 2026 | clinicaltrials |
| NCT03456843 | Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer | active not recruiting | Phase 2 | 190 | Yale UniversityOTHER | 6 | Jul 24, 2026 | clinicaltrials |
| NCT03957252 | Validation of ClarityDX Prostate as a Reflex Test to Refine the Prediction of Clinically-significant Prostate Cancer(APCaRI-05) | active not recruiting | — | 2,800 | NanosticsINDUSTRY | 2 | Jul 24, 2026 | clinicaltrials |
| NCT05113537 | Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer(UPLIFT) | recruiting | Phase 1 / Phase 2 | 30 | Vadim S KoshkinOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06014255 | Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer(HEAT) | active not recruiting | Phase 2 | 219 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06161506 | Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer | recruiting | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07725653 | Impact of Anterior Urethral Suspension Combined With Pelvic Fascia Reconstruction During Robot-Assisted Radical Prostatectomy on Early Postoperative Urinary Continence Recovery: A Single-Center, Prospective, Single-Arm Clinical Study(IAPREA) | completed | N/A | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT02303327 | Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients | active not recruiting | Phase 3 | 307 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT04471974 | ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 2 | 61 | Rahul AggarwalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT04553926 | 'OLAP' (OLAparib Regulatory Post-marketing Surveillance)(OLAP) | completed | — | 661 | AstraZenecaINDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05530655 | A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer | recruiting | Early Phase 1 | 30 | University of RochesterOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06022757 | Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) | terminated | Phase 1 / Phase 2 | 12 | Evopoint Biosciences Inc.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06228404 | Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC | active not recruiting | Early Phase 1 | 18 | Shanghai Changzheng HospitalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06238713 | Extraperitoneal SINgle-port rObotic-assisted Radical Prostatectomy (RARP) Versus Transperitoneal Multi-port RARP in the Treatment Of Prostate Cancer (SINO-TOP) | recruiting | N/A | 480 | Shanghai Changzheng HospitalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06509919 | Application of a Novel Model Based on Plasma cfDNA Assay and MRl Imaging in the Detection of Prostate Cancer | suspended | — | 1,600 | Shanghai Changzheng HospitalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06545942 | Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 220 | MOMA TherapeuticsINDUSTRY | 3 | Jul 23, 2026 | clinicaltrials |
| NCT06589154 | The Application of Multimodal Artificial Intelligence Systems in Prostate Cancer Diagnosis and Prognosis Analysis | completed | — | 1,651 | Shanghai Changzheng HospitalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06895811 | Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC | active not recruiting | Phase 1 | 3 | Shanghai Changzheng HospitalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06942104 | Imaging of Solid Tumors Using 18F-TRX | recruiting | Phase 1 | 56 | Rahul AggarwalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07042243 | The Florida ASCENT Study | recruiting | N/A | 100 | University of FloridaOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07052214 | PSMA PET Combined With MRI for the Detection of PCa(BiPASS) | recruiting | Phase 3 | 338 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 2 | Jul 23, 2026 | clinicaltrials |
| NCT07641855 | A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer | not yet recruiting | Phase 2 / Phase 3 | 180 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07711314 | Adjuvant Rezvilutamide Monotherapy for High-Risk Prostate Cancer After Radical Prostatectomy(ARMOR) | recruiting | Phase 2 | 48 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07721532 | Observing the Real-world Non-interventional Study of Abiraterone Acetate Tablets (II) in Treating Chinese Patients With Metastatic Prostate Cancer(prostate) | active not recruiting | — | 3,000 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07721935 | Development of an AI-Agent for Urological Disease Diagnosis and Treatment | recruiting | — | 2,000 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07723651 | [18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC) | not yet recruiting | Phase 2 | 75 | Washington University School of MedicineOTHER | 1 | Jul 23, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 30, 2026source: clinicaltrials